Drugs that contain Alogliptin Benzoate; Pioglitazone Hydrochloride

1. List of Oseni drug patents

Can you believe OSENI received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 11 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(1 year, 11 months from now)

US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone
Jun, 2029

(6 years from now)

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

More Information on Dosage

OSENI family patents

12

United States

9

China

6

Japan

4

Taiwan, Province of China

3

Israel

3

Argentina

3

Korea, Republic of

2

South Africa

2

Denmark

2

Austria

2

Mexico

2

Australia

2

Hong Kong

2

Slovenia

2

Morocco

2

Norway

2

Costa Rica

2

Germany

2

Brazil

2

Croatia

2

Portugal

2

Cyprus

2

Malaysia

2

Spain

2

Poland

2

RS

2

Georgia

2

Ukraine

EA

2

EA

2

Canada

2

New Zealand

2

European Union

1

Jordan

1

Hungary

1

Netherlands

1

Dominican Republic

1

Peru

1

Chile

1

Ecuador

1

Luxembourg

1

Tunisia

1

ME

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in